PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare lymphoma: targeted drug combo shows promise
Disease control CompletedThis study tested a treatment called DA-EPOCH-Rituximab in 47 children and teens with a rare type of lymphoma (PMLBL). The goal was to see if this combination of chemotherapy and a targeted antibody could keep the cancer from coming back. The trial measured how long patients live…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New CAR-T therapy shows promise for tough lymphoma cases
Disease control CompletedThis early-phase study tested a new treatment called BZ019 for adults with B-cell lymphoma that came back or didn't respond to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and see if the tr…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC